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depended on their vote at the first round of the 2017 
presidential election (figure): those who had voted for a 
far left or far right candidate were much more likely to 
state that they would refuse the vaccine, as well as those 
who abtained from voting.
These early results are not entirely surprising. When 
this dimension has been studied, researchers have 
often found a connection between political beliefs 
and attitudes to vaccines.6 They highlight a crucial 
issue for public health interventions: how can we 
assure the public that recommendations reflect the 
state of scientific knowledge rather than political 
interests? This problem is exacerbated in times of 
crisis, during which there is considerable scientific 
uncertainty, available measures have a limited effect, 
and politicians—rather than experts—are the public 
face of crisis management. This is one of the lessons 
that can be drawn from the H1N1 influenza pandemic 
of 2009 in France. As the pandemic unfolded, the 
apparent national unity of the early phase broke apart. 
Criticism of the government’s strategy was voiced by 
prominent members of nearly all of the opposition 
parties.7 A public debate around the safety of the 
vaccine arose, with prominent politicians and activists 
claiming that it had been produced too hastily and not 
been tested enough. This was crucial in the failure of 
the vaccination campaign (only 8% of the population 
was vaccinated).8 It also ushered in an era of perpetual 
debate over vaccination in France.9 One of the crucial 
mistakes made at the time by French authorities was to 
refuse to communicate early on the measures taken to 
ensure the safety of the vaccine for fear that the mere 
evocation of risk might provoke irrational reactions.10 
This approach let critics set the agenda on this 
issue, condemning public authorities to a defensive 
position. 
Public authorities are setting up fast-track approval 
processes for a putative vaccine against SARS-CoV-2.9 
It is crucial to communicate early and transparently on 
these processes to avoid vaccines becoming part of 
political debates.
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Global outbreak research: harmony not hegemony
To make clinical and biological observations within 
a time frame that is likely to benefit patients during 
disease out breaks, coordination of global research must 
match the speed of spread of novel pathogens. Time is 
short. Circumstances call for international collaboration 
to understand, treat, and prevent coronavirus disease 
2019 (COVID-19).
During previous infectious disease outbreaks, clinical 
research has often been established on an ad-hoc 
basis and done in silos, using different methodologies 
and designs. This approach limits opportunities to 
compare results, or to combine smaller studies to 
obtain answers quickly. Thus, perhaps it is self-evident 
that harmonisation of clinical investigation during 
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outbreaks is desirable. In a meeting of the WHO clinical 
management research prioritisation group held in 
January, 2020, harmonised clinical characterisation 
research was identified as the first priority for 
COVID-19.
Harmonisation creates opportunities for individual 
investigators to compare results or collaborate, with-
out applying burdens or obligations. In our experience, 
the quality and breadth of research is improved by 
collaborative development and peer review of shared 
protocols. For example, in the current outbreak, a 
clinician might design a study to identify risk factors for 
progression, co-infections, and mechanisms of critical 
illness. However, clinicians might overlook the need to 
obtain serum for research groups with the capability to 
make new assays for seroepidemiology, or peripheral 
blood mononuclear cells for monoclonal antibody 
therapeutics during this process. Wide collaboration leads 
to better, faster science.
Achieving global coordination is difficult enough at the 
best of times; during a crisis it might seem impossible. 
But with each new crisis, the same questions arise again 
and again, and so, the same designs can be used to tackle 
them. We believe that global harmonisation is possible, 
at least in the intermittently indispensable field of 
outbreak research. To achieve such a goal, harmonised 
investigation needs to be made easier than establishing 
isolated independent studies, must respect autonomy 
and sovereignty of investigators, and relinquish normal 
routes of academic recognition for this work.
To this end, in 2012, a single, standardised generic 
research protocol was created for clinical characterisation 
of any emerging infection (the International Severe 
Acute Respiratory and Emerging Infection Consortium 
[ISARIC]/WHO Clinical Characterisation Protocol [CCP]), 
which was the result of many years of international 
and cross-speciality consensus-building.1 Since the 
fundamental research questions in a new outbreak are 
predictable, the protocol can be established and approved 
in so-called peacetime, maintained in a hibernating state, 
then rapidly implemented when required. Carefully 
designed, flexible biological sampling schedules are 
included in tiers according to local resources, modular 
additional studies for specific situations, and scalable case 
report forms.1 These tools were released under an open-
source licence—ie, anyone can download these materials 
and use, adapt, or distribute them. Clinical research can 
feel like it is 95% about filling in forms. We filled in some 
of the forms, so you don’t have to.
In 2016, the ISARIC/WHO CCP was implemented 
in Brazil in response to the emergence of Zika virus 
and chikungunya virus in Latin America, facilitating 
studies of viral shedding and serology.2 The CCP was 
also used for the establishment of cohort studies 
of critically ill patients with Middle East respiratory 
syndrome.3 At present, the Uganda Virus Research 
Institute (Entebbe, Uganda) is using the protocol to 
study severe acute febrile illness and severe influenza.4 
The value of this approach is becoming apparent in 
the age of COVID-19. The original reports on clinical 
findings in COVID-19 used harmonised data collection.5,6 
46 countries have registered to record clinical data using 
the ISARIC/WHO CCP Case Report Form and investi-
gators in many countries are planning to use the CCP 
biological sampling protocol to coordinate studies 
of transmission, prognostication, pathogenesis, and 
diagnostics (appendix).
Understanding the genetic mechanisms underlying 
susceptibility7 might directly advance our understanding 
of disease mechanisms8 and possible treatments,9 but 
robust studies require recruitment of large numbers of 
critically ill patients, which requires open, collegiate, and 
global collaboration. Genetics Of Mortality In Critical 
Care is an open consortium in which clinicians have been 
recruiting critically ill patients since 2016. Importantly, 
this work is led by the clinicians treating the patients, in 
collaboration with experts in host genetics.
Operating clinical trials at global scale presents 
many additional challenges, but even in this domain, 
substantial progress has been made. Before the 
COVID-19 pandemic, the critical care community 
created a highly efficient, randomised, embedded 
multifactorial adaptive platform trial for community-
acquired pneumonia (REMAP-CAP). This single trial 
was established in 13 countries with the capacity to test 
new hypotheses quickly. Perhaps most ambitious of all, 
WHO has developed a global platform—the SOLIDARITY 
trial10—for the evaluation of widely-available inter-
ventions to treat COVID-19.
Catastrophes, such as pandemics, drive innovation 
and lead to marked social change. Within the scientific 
research community, we believe that perceptions of 
academic excellence have long undervalued teamwork 
and collegiality. We hope our colleagues across the world 
For more on the 
ISARIC/WHO CCP see https://
isaric.net/ccp/
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will make use of these tools, either in collaboration or 
independently, to harmonise clinical research efforts 
and fulfil the duties of medical science to humanity in 
the shortest time possible.
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